Koninklijke Philips (NYSE:PHG) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Koninklijke Philips (NYSE:PHG) announced its earnings results on Wednesday. The technology company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.01), Zacks reports. Koninklijke Philips had a negative net margin of 1.83% and a positive return on equity of 10.11%.

Koninklijke Philips Price Performance

PHG stock opened at $25.06 on Thursday. Koninklijke Philips has a 1 year low of $19.55 and a 1 year high of $32.91. The firm has a market cap of $23.55 billion, a P/E ratio of -59.65, a PEG ratio of 0.93 and a beta of 0.77. The stock’s 50 day moving average price is $26.26 and its 200 day moving average price is $28.18. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.74 and a current ratio of 1.16.

Analyst Upgrades and Downgrades

PHG has been the topic of several research analyst reports. UBS Group upgraded shares of Koninklijke Philips from a “neutral” rating to a “buy” rating in a research note on Thursday. Jefferies Financial Group raised shares of Koninklijke Philips from an “underperform” rating to a “hold” rating in a research report on Tuesday, October 29th. Finally, StockNews.com lowered shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a research note on Thursday, November 14th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Koninklijke Philips presently has a consensus rating of “Hold”.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.